• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PolyPid Ltd.

    2/12/25 7:05:02 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYPD alert in real time by email
    6-K 1 ea0230493-6k_polypid.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of February 2025

     

    Commission file number: 001-38428

     

    PolyPid Ltd.

    (Translation of registrant’s name into English)

     

    18 Hasivim Street

    Petach Tikva 495376, Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F          ☐ Form 40-F

     

     

     

     

     

     

    CONTENTS

     

    Appointment of New Director

     

    On February 12, 2025, PolyPid Ltd. (the “Company”) announced the appointment of Yitzchak Jacobovitz to its Board of Directors (the “Board”), effective February 10, 2025.

     

    Mr. Jacobovitz, age 49, currently is a partner at AIGH Capital Management, a position he has held since 2014. He has served as a director at the board of directors of Myomo, Inc. (NYSE American: MYO) since January 2023. Prior to his current positions, Mr. Jacobovitz was a managing director at Capstone, a policy research firm, and an analyst at Leap Tide Capital, a special situations hedge fund. Mr. Jacobovitz earned his Masters in Business Administration from Johns Hopkins University and is a Chartered Financial Analyst.

     

    The Board concluded that Mr. Jacobovitz is qualified to serve as a Director and is independent under the rules of the Nasdaq Stock Market. Mr. Jacobovitz has agreed not to receive compensation for his service as a Director. The Company expects to enter into its standard indemnification agreement with Mr. Jacobovitz, on substantially the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. Mr. Jacobovitz is not a party to any transactions that are disclosable under Item 7.B of Form 20-F.

     

    Issuance of Press Release

     

    Attached hereto and incorporated herein is the Company’s press release issued on February 12, 2025, titled “PolyPid Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results.”

     

    The bullet points under the section titled “Recent Corporate Highlights,” the sections titled “Financial results for three months ended December 31, 2024”, “Financial results for the full year ended December 31, 2024”, “Balance Sheet Highlights,” and “Forward-looking Statements” and the financial statements in the press release are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658 and File No. 333-281863) and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703 and File No. 333-280662) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Exhibit No.    
    99.1   Press Release issued by PolyPid Ltd. on February 12, 2025, titled “PolyPid Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results.”

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      POLYPID LTD.
         
    Date: February 12, 2025 By: /s/ Dikla Czaczkes Akselbrad
        Name:  Dikla Czaczkes Akselbrad
        Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $PYPD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PYPD

    DatePrice TargetRatingAnalyst
    6/5/2025$9.00Buy
    Roth Capital
    6/2/2025$11.00Buy
    H.C. Wainwright
    1/28/2025$13.00Buy
    Rodman & Renshaw
    2/11/2022$23.00 → $17.00Strong Buy
    Raymond James
    9/14/2021$14.00Market Outperform
    JMP Securities
    7/30/2021$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PYPD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

      PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025Time:8:30 AM Easte

      6/6/25 4:05:00 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

      PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 10:15 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2025/ or directly at https://app.webinar.net/QyL1ZkGZK8z. The webcast will also be available for replay following the

      5/20/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

      PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2025. Recent Corporate Highligh

      5/14/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      12/12/24 7:05:07 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      11/29/24 1:20:33 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

      SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

      10/28/24 4:01:03 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    SEC Filings

    See more
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      5/30/25 4:05:39 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      5/21/25 4:05:07 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PolyPid Ltd.

      6-K - PolyPid Ltd. (0001611842) (Filer)

      5/14/25 7:13:44 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Financials

    Live finance-specific insights

    See more
    • PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

      PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025Time:8:30 AM Easte

      6/6/25 4:05:00 PM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

      PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2025. Recent Corporate Highligh

      5/14/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

      PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of ma

      4/29/25 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Leadership Updates

    Live Leadership Updates

    See more
    • PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

      PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic

      11/7/23 7:00:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

      Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Berger, M.D., to its Oncology Advisory Board. Dr. Berger is the Berthold and Belle N. Guggenhime Professor of the Department of Neurological Surgery at the University of California, San Francisco (U

      1/4/22 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PolyPid Announces Planned CEO Transition

      PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company's Executive Vice President and Chief Financial Officer, as PolyPid's Chief Executive Officer, effective July 1, 2022. Amir Weisberg, who currently serves as Chief Executive Officer and a director, will direct a transition period with Ms. Czaczkes Akselbrad beginning on April 1, 2022, and will retire from the Chief

      1/3/22 7:30:00 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on PolyPid Ltd. with a new price target

      Roth Capital initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $9.00

      6/5/25 7:35:43 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on PolyPid Ltd. with a new price target

      H.C. Wainwright resumed coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $11.00

      6/2/25 8:53:56 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on PolyPid Ltd. with a new price target

      Rodman & Renshaw initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $13.00

      1/28/25 7:16:12 AM ET
      $PYPD
      Biotechnology: Pharmaceutical Preparations
      Health Care